These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 717288)
1. Combined vs. single-drug studies of susceptibilities of Mycobacterium kansasii to isoniazid, streptomycin, and ethambutol. Tsang AY; Bentz RR; Schork MA; Sodeman TM Am J Clin Pathol; 1978 Nov; 70(5):816-20. PubMed ID: 717288 [TBL] [Abstract][Full Text] [Related]
2. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Banks J; Jenkins PA Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264 [TBL] [Abstract][Full Text] [Related]
3. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. Wallace RJ; Nash DR; Steele LC; Steingrube V J Clin Microbiol; 1986 Dec; 24(6):976-81. PubMed ID: 3097069 [TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Heifets LB Am Rev Respir Dis; 1982 Jan; 125(1):43-8. PubMed ID: 7065508 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Hjelm U; Kaustová J; Kubín M; Hoffner SE Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):51-4. PubMed ID: 1563386 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing]. Tsukamura M Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008 [TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Dickinson JM; Aber VR; Mitchison DA Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404 [TBL] [Abstract][Full Text] [Related]
8. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases. Yamori S; Ichiyama S; Shimokata K; Tsukamura M Microbiol Immunol; 1992; 36(4):361-8. PubMed ID: 1406364 [TBL] [Abstract][Full Text] [Related]
9. [Distribution and drug resistance of nontuberculous Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817 [No Abstract] [Full Text] [Related]
10. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553 [TBL] [Abstract][Full Text] [Related]
11. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. Kuze F; Kurasawa T; Bando K; Lee Y; Maekawa N Rev Infect Dis; 1981; 3(5):885-97. PubMed ID: 7339820 [TBL] [Abstract][Full Text] [Related]
14. [Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS]. Ibarrola M; Baraia-Etxaburu J; Sánchez R; Teira R; Unzaga J; Miguel Santamaría J Enferm Infecc Microbiol Clin; 2001 Feb; 19(2):80-2. PubMed ID: 11333577 [No Abstract] [Full Text] [Related]
15. In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex. Zimmer BL; DeYoung DR; Roberts GD Antimicrob Agents Chemother; 1982 Jul; 22(1):148-50. PubMed ID: 7125626 [TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease]. Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533 [No Abstract] [Full Text] [Related]
17. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674 [TBL] [Abstract][Full Text] [Related]
18. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736 [TBL] [Abstract][Full Text] [Related]
19. A comparison of the E-test and proportion methods for susceptibility testing of Mycobacterium tuberculosis. Sanic A; Gunaydin M; Coban AY; Tokac ; Cetin M J Chemother; 2000 Dec; 12(6):491-4. PubMed ID: 11154031 [TBL] [Abstract][Full Text] [Related]
20. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]